A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer

Brian G. Barnett,Jens Rüter,Michael J. Brumlik,Ilona Kryczek,Pui Cheng,Weiping Zou,Tyler J. Curiel

A phase II trial of denileukin diftitox to treat refractory advanced-stage ovarian cancer

2006

Brian G. Barnett
Jens Rüter
Michael J. Brumlik
Ilona Kryczek
Pui Cheng
Weiping Zou
Tyler J. Curiel

2506 Background: Denileukin diftitox is a fusion toxin consisting of interleukin-2 genetically fused to diphtheria toxin. It is approved to treat cutaneous T cell lymphoma. Our recent Phase I trial...

Keywords:

Ovarian cancer
Denileukin diftitox
Cancer research
Medicine
Fusion Toxin
Pathology
advanced stage
Cutaneous T-cell lymphoma
Refractory
Diphtheria toxin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations